WuXi Biologics (Cayman) (OTCMKTS:WXXWY) Sets New 1-Year High – Here’s Why

WuXi Biologics (Cayman) Inc. (OTCMKTS:WXXWY – Get Free Report) hit a new 52-week high during mid-day trading on Wednesday. The stock traded as high as $14.38 and last traded at $14.33, with a volume of 20357 shares changing hands. The stock had previously closed at $13.66.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of WuXi Biologics (Cayman) to a “hold” rating in a research report on Friday, August 28th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Get WuXi Biologics (Cayman) alerts:

Read Our Latest Stock Analysis on WuXi Biologics (Cayman)

WuXi Biologics (Cayman) Trading Up 5.0%

The company has a fifty day simple moving average of $11.97 and a 200-day simple moving average of $9.83.

About WuXi Biologics (Cayman)

(Get Free Report)

WuXi Biologics (Cayman) Inc is a global contract research, development and manufacturing organization (CRDMO) focused on biologic medicines. The company works with pharmaceutical and biotechnology customers to support the development and production of biologic therapies, including monoclonal antibodies, recombinant proteins, vaccines and other complex biological products.

Its services span early-stage discovery and cell-line development through process development, clinical manufacturing, regulatory support and commercial-scale production.

Further Reading

• Five stocks we like better than WuXi Biologics (Cayman)
• Arhaus Has New Momentum—Could Other Furniture Stocks Be Next?
• Can Boxabl Turn Modular Homes Into AI Data Center Infrastructure?
• Up All Night: How Nasdaq’s 23-Hour Trading Could Wake Up Wall Street
• 4 Stocks That Could Split Next—and Why Investors Are Watching

Receive News & Ratings for WuXi Biologics (Cayman) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi Biologics (Cayman) and related companies with MarketBeat.com's FREE daily email newsletter.